Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BioNTech SE
Sanofi and GSK are way behind in the COVID-19 vaccine race and the start of a rolling review of Vizprevtyn at the European Medicines Agency is an important step.
Benefits of the one-shot vaccine outweigh risk, ACIP members agree. One member says he supports its availability but would personally recommend mRNA vaccines instead.
Pfizer agreed to pay up to $2.4bn to share development and commercialization costs for Arvinas’ estrogen receptor degrader, including in combination with Ibrance.
The company's pharma revenues grew 17.2% in the second quarter against favorable comparisons and as the COVID-19 pandemic recovery continued.
- Antisense, Oligonucleotides
- Large Molecule
- Other Names / Subsidiaries
- BioNTech US Inc.
- Biopharmaceutical New Technologies AG
- Neon Therapeutics, Inc.
- BioNTech AG